Publications by authors named "Peter Hiestand"

15Publications

Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions.

Authors:
Timothy J Seabrook Amanda Littlewood-Evans Volker Brinkmann Bernadette Pöllinger Christian Schnell Peter C Hiestand

J Neuroinflammation 2010 Dec 22;7:95. Epub 2010 Dec 22.

Department of Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
December 2010

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.

Authors:
Laszlo Revesz Achim Schlapbach Reiner Aichholz Roland Feifel Stuart Hawtin Richard Heng Peter Hiestand Wolfgang Jahnke Guido Koch Markus Kroemer Henrik Möbitz Clemens Scheufler Juraj Velcicky Christine Huppertz

Bioorg Med Chem Lett 2010 Aug 13;20(15):4715-8. Epub 2010 Apr 13.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
August 2010

Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.

Authors:
Osamu Irie Takatoshi Kosaka Masashi Kishida Junichi Sakaki Keiichi Masuya Kazuhide Konishi Fumiaki Yokokawa Takeru Ehara Atsuko Iwasaki Yuki Iwaki Yuko Hitomi Atsushi Toyao Hiroki Gunji Naoki Teno Genji Iwasaki Hajime Hirao Takanori Kanazawa Keiko Tanabe Peter C Hiestand Marzia Malcangio Alyson J Fox Stuart J Bevan Mohammed Yaqoob Andrew J Culshaw Terance W Hart Allan Hallett

Bioorg Med Chem Lett 2008 Oct 22;18(19):5280-4. Epub 2008 Aug 22.

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan.

View Article and Find Full Text PDF
October 2008

Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.

Authors:
Peter C Hiestand Martin Rausch Daniela Piani Meier Carolyn A Foster

Prog Drug Res 2008 ;66:361, 363-81

Novartis Pharma AG, Lichtstrasse 35, 4002 Basel, Switzerland.

View Article and Find Full Text PDF
May 2008

FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.

Authors:
Balázs Balatoni Maria K Storch Eva-M Swoboda Vinzenz Schönborn Agnieszka Koziel George N Lambrou Peter C Hiestand Robert Weissert Carolyn A Foster

Brain Res Bull 2007 Oct 30;74(5):307-16. Epub 2007 Jul 30.

Novartis Institutes for BioMedical Research, Brunner Strasse 59, A-1235, Vienna, Austria.

View Article and Find Full Text PDF
October 2007

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.

Authors:
Carolyn A Foster Laurence M Howard Alain Schweitzer Elke Persohn Peter C Hiestand Balázs Balatoni Roland Reuschel Christian Beerli Manuela Schwartz Andreas Billich

J Pharmacol Exp Ther 2007 Nov 6;323(2):469-75. Epub 2007 Aug 6.

Novartis Institutes for BioMedical Research, Vienna, Austria.

View Article and Find Full Text PDF
November 2007

In vivo monitoring the fate of Cy5.5-Tat labeled T lymphocytes by quantitative near-infrared fluorescence imaging during acute brain inflammation in a rat model of experimental autoimmune encephalomyelitis.

Authors:
Cedric Berger Hans-Ulrich Gremlich Philipp Schmidt Catherine Cannet Rainer Kneuer Peter Hiestand Martin Rausch Markus Rudin

J Immunol Methods 2007 May 22;323(1):65-77. Epub 2007 Mar 22.

Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
May 2007

Analysis of lesion development during acute inflammation and remission in a rat model of experimental autoimmune encephalomyelitis by visualization of macrophage infiltration, demyelination and blood-brain barrier damage.

Authors:
Cedric Berger Peter Hiestand Diana Kindler-Baumann Markus Rudin Martin Rausch

NMR Biomed 2006 Feb;19(1):101-7

Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
February 2006

Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.

Authors:
Laszlo Revesz Ernst Blum Franco E Di Padova Thomas Buhl Roland Feifel Hermann Gram Peter Hiestand Ute Manning Ulf Neumann Gerard Rucklin

Bioorg Med Chem Lett 2006 Jan 24;16(2):262-6. Epub 2005 Oct 24.

Novartis Institutes for BioMedical Research, Global Discovery Chemistry, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
January 2006

Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.

Authors:
Laszlo Revesz Birgit Bollbuck Thomas Buhl Joerg Eder Ronald Esser Roland Feifel Richard Heng Peter Hiestand Benedicte Jachez-Demange Pius Loetscher Helmut Sparrer Achim Schlapbach Rudolf Waelchli

Bioorg Med Chem Lett 2005 Dec 28;15(23):5160-4. Epub 2005 Sep 28.

Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Autoimmunity and Transplantation, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
December 2005

Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.

Authors:
Martin Rausch Peter Hiestand Carolyn A Foster Diana R Baumann Catherine Cannet Markus Rudin

J Magn Reson Imaging 2004 Jul;20(1):16-24

Novartis Institute for Biomedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.

Authors:
Laszlo Revesz Ernst Blum Franco E Di Padova Thomas Buhl Roland Feifel Hermann Gram Peter Hiestand Ute Manning Gerard Rucklin

Bioorg Med Chem Lett 2004 Jul;14(13):3601-5

Novartis Institutes for BioMedical Research, Arthritis and Bone Metabolism, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.

Authors:
Laszlo Revesz Ernst Blum Franco E Di Padova Thomas Buhl Roland Feifel Hermann Gram Peter Hiestand Ute Manning Gerard Rucklin

Bioorg Med Chem Lett 2004 Jul;14(13):3595-9

Novartis Institutes for BioMedical Research, Arthritis & Bone Metabolism, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.

Authors:
Laszlo Revesz Franco E Di Padova Thomas Buhl Roland Feifel Hermann Gram Peter Hiestand Ute Manning Romain Wolf Alfred G Zimmerlin

Bioorg Med Chem Lett 2002 Aug;12(16):2109-12

Arthritis and Bone Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF
August 2002

The immune modulator FTY720 targets sphingosine 1-phosphate receptors.

Authors:
Volker Brinkmann Michael D Davis Christopher E Heise Rainer Albert Sylvain Cottens Robert Hof Christian Bruns Eva Prieschl Thomas Baumruker Peter Hiestand Carolyn A Foster Markus Zollinger Kevin R Lynch

J Biol Chem 2002 Jun 19;277(24):21453-7. Epub 2002 Apr 19.

Department of Transplantation, Novartis Pharma AG, Lichtstrasse 35, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
June 2002